EUR 11.75
(1.29%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 95.25 Million EUR | -2.69% |
2022 | 94.96 Million EUR | 2.62% |
2021 | 103.64 Million EUR | -10.9% |
2020 | 81.44 Million EUR | 17.84% |
2019 | 78.04 Million EUR | 20.46% |
2018 | 57.08 Million EUR | -17.77% |
2017 | 75.2 Million EUR | 11.05% |
2016 | 56.01 Million EUR | 20.13% |
2015 | 74.32 Million EUR | -76.35% |
2014 | 308.57 Million EUR | 120.25% |
2013 | 173.18 Million EUR | -2.21% |
2012 | 133.36 Million EUR | 1.72% |
2011 | 137.35 Million EUR | -42.89% |
2010 | 157.23 Million EUR | 57.55% |
2009 | 164.41 Million EUR | 6.82% |
2008 | 155.23 Million EUR | 46.38% |
2007 | 103.05 Million EUR | 7.61% |
2006 | 94.12 Million EUR | 49.42% |
2005 | 65.95 Million EUR | -17.34% |
2004 | 81.92 Million EUR | -4.64% |
2003 | 80.58 Million EUR | 32.41% |
2002 | 61.39 Million EUR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 21.03 Million EUR | -16.08% |
2024 Q2 | 21.03 Million EUR | 0.0% |
2023 FY | - EUR | -2.69% |
2023 Q4 | 25.06 Million EUR | 0.0% |
2023 Q2 | 19.59 Million EUR | 0.0% |
2023 Q1 | 19.59 Million EUR | -12.2% |
2023 Q3 | 25.06 Million EUR | 27.91% |
2022 Q3 | 22.31 Million EUR | -44.23% |
2022 Q1 | 15.88 Million EUR | -72.77% |
2022 Q4 | 22.31 Million EUR | 0.0% |
2022 Q2 | 40.02 Million EUR | 151.97% |
2022 FY | - EUR | 2.62% |
2021 FY | - EUR | -10.9% |
2021 Q1 | 17.06 Million EUR | -73.67% |
2021 Q2 | 42.38 Million EUR | 148.38% |
2021 Q4 | 58.32 Million EUR | 129.39% |
2021 Q3 | 25.42 Million EUR | -40.02% |
2020 Q3 | 31.22 Million EUR | -14.31% |
2020 Q2 | 36.44 Million EUR | 152.7% |
2020 FY | - EUR | 17.84% |
2020 Q1 | 14.42 Million EUR | -73.67% |
2020 Q4 | 64.81 Million EUR | 107.54% |
2019 Q4 | 54.76 Million EUR | 133.3% |
2019 Q2 | 18.05 Million EUR | 0.0% |
2019 Q1 | 18.05 Million EUR | -15.33% |
2019 FY | - EUR | 20.46% |
2019 Q3 | 23.47 Million EUR | 30.01% |
2018 FY | - EUR | -17.77% |
2018 Q1 | 15.99 Million EUR | -31.79% |
2018 Q2 | 15.99 Million EUR | 0.0% |
2018 Q3 | 21.32 Million EUR | 33.27% |
2018 Q4 | 21.32 Million EUR | 0.0% |
2017 Q1 | 14.14 Million EUR | -57.23% |
2017 Q4 | 23.45 Million EUR | 0.0% |
2017 Q3 | 23.45 Million EUR | 65.8% |
2017 FY | - EUR | 11.05% |
2017 Q2 | 14.14 Million EUR | 0.0% |
2016 Q2 | 26.08 Million EUR | 69.22% |
2016 Q1 | 15.41 Million EUR | -13.39% |
2016 Q3 | 18.27 Million EUR | -29.97% |
2016 Q4 | 33.07 Million EUR | 81.06% |
2016 FY | - EUR | 20.13% |
2015 Q2 | 19.22 Million EUR | -14.62% |
2015 FY | - EUR | -76.35% |
2015 Q4 | 17.8 Million EUR | -3.6% |
2015 Q3 | 18.46 Million EUR | -3.93% |
2015 Q1 | 22.51 Million EUR | -90.63% |
2014 FY | - EUR | 120.25% |
2014 Q4 | 240.37 Million EUR | 680.54% |
2014 Q3 | 30.79 Million EUR | -26.21% |
2014 Q2 | 41.73 Million EUR | 180.06% |
2014 Q1 | 14.9 Million EUR | -71.69% |
2013 Q2 | 28.91 Million EUR | 10.16% |
2013 Q3 | 40.59 Million EUR | 40.39% |
2013 Q4 | 52.63 Million EUR | 29.66% |
2013 FY | - EUR | -2.21% |
2013 Q1 | 26.24 Million EUR | -57.43% |
2012 Q4 | 61.66 Million EUR | 170.6% |
2012 Q1 | 19.97 Million EUR | 0.0% |
2012 Q2 | 158.35 Million EUR | 692.79% |
2012 Q3 | -87.33 Million EUR | -155.15% |
2012 FY | - EUR | 1.72% |
2011 FY | - EUR | -42.89% |
2010 FY | - EUR | 57.55% |
2009 FY | - EUR | 6.82% |
2008 FY | - EUR | 46.38% |
2007 FY | - EUR | 7.61% |
2006 FY | - EUR | 49.42% |
2005 FY | - EUR | -17.34% |
2004 FY | - EUR | -4.64% |
2003 FY | - EUR | 32.41% |
2002 FY | - EUR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Guerbet SA | 90.09 Million EUR | -5.724% |
Nexus AG | 53.43 Million EUR | -78.269% |
Bastide Le Confort Médical SA | 110.32 Million EUR | 13.662% |
Revenio Group Oyj | 30.09 Million EUR | -216.554% |
Drägerwerk AG & Co. KGaA | 318.33 Million EUR | 70.078% |
Sartorius Aktiengesellschaft | 811.2 Million EUR | 88.258% |
LNA Santé SA | 144.63 Million EUR | 34.144% |
Siemens Healthineers AG | 4.22 Billion EUR | 97.746% |
Medios AG | 52.81 Million EUR | -80.345% |
Equasens Société anonyme | 71.29 Million EUR | -33.594% |
Stratec SE | 39.82 Million EUR | -139.198% |